Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?
Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.
Pharma & Biotech
Pharma & Biotech
Could Therorna’s circRNA in vivo CAR-T platform change autoimmune disease treatment?
CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.
Pharma & Biotech
How Imviva Biotech is positioning allogeneic CAR-T therapy for autoimmune disease disruption
Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.
Pharma & Biotech
Tempest Therapeutics, Inc. bets on dual-targeting CAR-T to address antigen escape challenges
Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.
Pharma & Biotech
Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?
Obsidian Therapeutics will present OBX-115 melanoma data at ASCO 2026. Read why the update matters for TIL therapy, scalability, and solid tumor strategy.
Pharma & Biotech
Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
Read how Agenus’ AACR 2026 data could reshape treatment sequencing in refractory gastroesophageal cancer and what risks still matter.
Pharma & Biotech
Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
Discover how FT839’s conditioning-free CAR T platform could reshape cancer and autoimmune treatment pathways. Read the full analysis now.
Pharma & Biotech
Can IASO Bio and Instituto Butantan make CAR-T therapy affordable for Brazil’s public health system?
IASO Bio and Instituto Butantan are betting on local CAR-T development in Brazil. Find out what this could change for access, cost, and cancer care.
Pharma & Biotech
What the Agenus-MiNK Therapeutics combination reveals about the next phase of GI cancer immunotherapy
Agenus brings botensilimab, balstilimab, and agenT-797 to AACR 2026. Read why this refractory GEC update matters and what risks remain.
Pharma & Biotech
Why Gilead’s Arcellx tender extension matters more for cell therapy execution than for deal timing
Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.